340B Expansion, Revisions Becoming Front-Burner Issues For Pharma
Executive Summary
Moves to expand and revise the federal 340B drug discount program as part of broad health care reform legislation are becoming high-profile concerns in the pharmaceutical industry
You may also be interested in...
Final Health Reform Bill Looks Positive For Pharma Firms
It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result
Final Health Reform Bill Looks Positive For Pharma Firms
It has been a long haul to get to the final iteration of proposed health care reform legislation released March 18, and it appears that the pharmaceutical industry's patience and lobbying efforts have garnered an overall positive result
340B For All? Rx Discount Expansion Coming -- With Or Without Health Reform
The pharmaceutical industry should prepare for an expansion of the 340B drug discount program in the U.S. - regardless of the outcome of the health care reform debate